Hexagon | AutonomouStuff Webinar Showcases How Velodyne’s Velarray H800 and PAEB Solution Can Power Advanced Driver Assistance Systems (ADAS) and Autonomy
8.12.2020 16:00:00 EET | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR) today announced Dr. Mircea Gradu, the company’s Senior Vice President of Product and Quality, is the featured speaker at a Hexagon | AutonomouStuff webinar on how lidar solutions can enhance safety in consumer vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005231/en/
Velodyne Lidar’s Velarray H800 solid state lidar sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. (Photo: Velodyne Lidar, Inc.)
The free webinar, called “Automotive-grade solid-state lidar for ADAS and autonomy: Velodyne Velarray H800,” takes place on December 15, 2020 at 2:00 p.m. EST. It is being moderated by Nicole Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff. To register, please click here.
The webinar will focus on the Velarray H800, Velodyne’s newly launched solid state lidar sensor designed for safe navigation and collision avoidance in advanced driver assistance systems (ADAS) and autonomous mobility applications. The Velarray H800 can help automakers design ADAS solutions that help reduce traffic accidents as well as injuries and deaths of drivers, passengers, bicyclists and pedestrians. The Velarray H800 is a key technology that will be used in systems for powerful vehicle safety, including for Automatic Emergency Braking, Lane Keep Assist and Adaptive Cruise Control.
The webinar will also cover Velodyne’s Pedestrian Automated Emergency Braking (PAEB) solution, which combines proprietary software, called Vella™, with Velodyne’s lidar sensors. Recent pedestrian crash statistics highlight an opportunity for PAEB systems to save thousands of lives annually by improving performance in dark conditions. According to the National Highway Traffic Safety Association, in 2018, 76% of the 6,283 total pedestrian crash fatalities in the U.S. occurred in dark conditions. Adding lidar can help address the risks that current PAEB systems present in frequently failing to protect pedestrians in dark conditions.
To demonstrate how PAEB systems can be achieved by utilizing lidar, Velodyne tested its lidar-based PAEB system against a highly-rated PAEB system built around camera and radar. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested. The combination of Velarray lidar data and Vella processing software dramatically improves PAEB performance, addressing a use case that causes thousands of pedestrian fatalities annually, and strengthening the vehicle’s functional safety achievements. For more information on the testing, please see Velodyne’s recently issued white paper regarding PAEB here.
“Lidar is an essential building block in creating advanced driving systems that improve vehicle, passenger and pedestrian safety. Webinar attendees can hear from a leading industry authority on how the Velarray H800 lidar sensor can help make cars and roadways safer for everyone,” said Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff.
“This webinar will discuss how automakers can significantly improve effectiveness and efficiency of vehicle driver-assist features and full autonomy by employing the Velarray H800. The sensor provides a revolutionary approach to making vehicles smarter and safer,” said Gradu.
Gradu leads Velodyne’s efforts to design, develop and manufacture world-class products compliant with international quality standards and is the 2018 President and Chairman of the Board of the Society of Automotive Engineers (SAE) International. He also is a Professor in the Mechanical and Aerospace Engineering Department at University of California Irvine (UCI), a member of UCI’s Institute for Transportation Studies Leadership Council and a FISITA Council member (International Federation of the Automotive Engineering Societies).
The Velarray H800 boasts outstanding range, field of view and resolution to support advancements in ADAS and autonomy, from Level 2 to Level 5. The sensor’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior. It is architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA).
About Velodyne Lidar
Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005231/en/
Contact information
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
